Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis.

[1]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[2]  J. Kastelein,et al.  Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia , 2003, Heart.

[3]  M. Trip,et al.  Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia. , 2003, The American journal of cardiology.

[4]  M. Trip,et al.  Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. , 2002, Atherosclerosis.

[5]  Allen J. Taylor,et al.  ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A Randomized Trial Comparing the Effects of Atorvastatin and Pravastatin on Carotid Intima Medial Thickness , 2002, Circulation.

[6]  U. Schminke,et al.  Volumetric Assessment of Plaque Progression With 3‐Dimensional Ultrasonography Under Statin Therapy , 2002, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[7]  H. Honest,et al.  Reporting of measures of accuracy in systematic reviews of diagnostic literature , 2002, BMC health services research.

[8]  S. Kashiwagi,et al.  Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). , 2002, Journal of the American College of Cardiology.

[9]  Moyses Szklo,et al.  Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987-1998. , 2002, American journal of epidemiology.

[10]  J. Hsia,et al.  Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. , 2001, The American journal of medicine.

[11]  M. Harada‐Shiba,et al.  Apheresis technology for prevention and regression of atherosclerosis. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[12]  V. Fuster,et al.  Effects of Lipid-Lowering by Simvastatin on Human Atherosclerotic Lesions: A Longitudinal Study by High-Resolution, Noninvasive Magnetic Resonance Imaging , 2001, Circulation.

[13]  S. Grundy,et al.  Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels , 2001, Circulation.

[14]  G. Berglund,et al.  Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness: Main Results From the &bgr;-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) , 2001, Circulation.

[15]  K. Dickstein,et al.  Effect of simvastatin in preventing progression of carotid artery stenosis. , 2001, The American journal of cardiology.

[16]  M. Trip,et al.  Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial , 2001, The Lancet.

[17]  W. Reitsma,et al.  Effects of initial and long-term lipid-lowering therapy on vascular wall characteristics. , 2001, Atherosclerosis.

[18]  Wollersheim,et al.  The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia , 2000, European journal of clinical investigation.

[19]  A. Folsom,et al.  Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. , 2000, American journal of epidemiology.

[20]  A. Seifalian,et al.  The effect of short-term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: a pilot study. , 2000 .

[21]  F. Raal,et al.  Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia. , 1999, The American journal of cardiology.

[22]  I. Olkin,et al.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.

[23]  G. Mancini,et al.  Carotid intima-media thickness measurements: what defines an abnormality? A systematic review. , 1999, Clinical and investigative medicine. Medecine clinique et experimentale.

[24]  M. Pfeffer,et al.  Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .

[25]  P. Chien,et al.  Misleading authors' inferences in obstetric diagnostic test literature. , 1999, American journal of obstetrics and gynecology.

[26]  A. Folsom,et al.  Relative importance of various risk factors for asymptomatic carotid atherosclerosis versus coronary heart disease incidence: the Atherosclerosis Risk in Communities Study. , 1999, American journal of epidemiology.

[27]  A. Zwinderman,et al.  B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). , 1998, Journal of the American College of Cardiology.

[28]  R. Rosenson,et al.  Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. , 1998, JAMA.

[29]  H. White,et al.  Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis Results of the LIPID Atherosclerosis Substudy , 1998 .

[30]  H. Wollersheim,et al.  Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increased intima-media thickness. , 1997, Clinical science.

[31]  A. Folsom,et al.  Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. , 1997, American journal of epidemiology.

[32]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[33]  Arno W. Hoes,et al.  Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. , 1997, Circulation.

[34]  R. Sacco,et al.  Race-ethnicity and determinants of carotid atherosclerosis in a multiethnic population. The Northern Manhattan Stroke Study. , 1997, Stroke.

[35]  R. Westendorp,et al.  Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. , 1997, Stroke.

[36]  R. Krauss,et al.  Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. , 1997, Circulation.

[37]  A. Stalenhoef,et al.  Effect of Apheresis of Low-Density Lipoprotein on Peripheral Vascular Disease in Hypercholesterolemic Patients with Coronary Artery Disease , 1996, Annals of Internal Medicine.

[38]  G. Gallus,et al.  Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. , 1996, The American journal of medicine.

[39]  P. Macfarlane,et al.  West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .

[40]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[41]  S. Azen,et al.  Reduction in Carotid Arterial Wall Thickness Using Lovastatin and Dietary Therapy , 1996, Annals of Internal Medicine.

[42]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[43]  A. Folsom,et al.  Variability in B-mode ultrasound measurements in the atherosclerosis risk in communities (ARIC) study. , 1996, Ultrasound in medicine & biology.

[44]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[45]  O. Wiklund,et al.  Intima-media thickness after cholesterol lowering in familial hypercholesterolemia. A three-year ultrasound study of common carotid and femoral arteries. , 1995, Atherosclerosis.

[46]  C. Furberg,et al.  Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study. , 1995, The American journal of cardiology.

[47]  J. Salonen,et al.  The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. , 1995, The American journal of cardiology.

[48]  D. E. Shapiro,et al.  Issues in combining independent estimates of the sensitivity and specificity of a diagnostic test. , 1995, Academic radiology.

[49]  C. Furberg,et al.  Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) , 1995, The American journal of cardiology.

[50]  P M Rautaharju,et al.  Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. , 1995, Stroke.

[51]  G. Levine,et al.  Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. , 1995, The New England journal of medicine.

[52]  P Glasziou,et al.  Meta-analytic methods for diagnostic test accuracy. , 1995, Journal of clinical epidemiology.

[53]  A. Hofman,et al.  Reproducibility of carotid vessel wall thickness measurements. The Rotterdam Study. , 1994, Journal of clinical epidemiology.

[54]  J. Gardin,et al.  Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. , 1994, American journal of epidemiology.

[55]  L E Moses,et al.  Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. , 1993, Statistics in medicine.

[56]  J. Strong,et al.  Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). , 1992, The American journal of cardiology.

[57]  R W Barnes,et al.  Reproducibility of Noninvasive Ultrasonic Measurement of Carotid Atherosclerosis: The Asymptomatic Carotid Artery Plaque Study , 1992, Stroke.

[58]  J. Ricco.  Intermittent claudication, heart disease risk factors, and mortality: Smith GD, Shipley MJ, Rose G. Circulation 1990;82: 1925–1931 , 1992 .

[59]  M J Shipley,et al.  Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. , 1990, Circulation.

[60]  M. Bond,et al.  Detection and monitoring of asymptomatic atherosclerosis in clinical trials. , 1989, The American journal of medicine.

[61]  P Pignoli,et al.  Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. , 1986, Circulation.